SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023).
Diagnosis
Guideline
Ovarian cancer
Treatment
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
15 Jul 2024
15 Jul 2024
Historique:
accepted:
17
05
2024
medline:
15
7
2024
pubmed:
15
7
2024
entrez:
15
7
2024
Statut:
aheadofprint
Résumé
In recent years, the incorporation of new strategies to the therapeutic armamentarium has completely changed the outcomes of epithelial ovarian cancer (EOC). The identification of new predictive and prognostic biomarkers has also enabled the selection of those patients more likely to respond to targeted agents. Nevertheless, EOC is still a highly lethal disease and resistance to many of these new agents is common. The objective of this guideline is to summarize the most relevant strategies to manage EOC, to help the clinician throughout the challenging diagnostic and therapeutic processes and to provide evidence-based recommendations.
Identifiants
pubmed: 39008159
doi: 10.1007/s12094-024-03531-3
pii: 10.1007/s12094-024-03531-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(10):833–48.
pubmed: 37597580
doi: 10.1016/j.annonc.2023.07.011
Sociedad Española de Oncología Médica (SEOM). Las cifras del cáncer en España 2023. Depósito Legal: M-3407-2023 ISBN: 978-84-09-48173-6 © 2023.
Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol. 2016;34(24):2888–98.
pubmed: 27325851
pmcid: 5012665
doi: 10.1200/JCO.2016.66.8178
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38(11):1222–45.
pubmed: 31986064
doi: 10.1200/JCO.19.02960
Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;319(6):595–606.
pubmed: 29450530
doi: 10.1001/jama.2017.21421
Timmerman D, Planchamp F, Bourne T, Landolfo Ch, du Bois A, Chiva L, et al. ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. Int J Gynecol Cancer. 2021;31(7):961–82.
pubmed: 34112736
pmcid: 8273689
doi: 10.1136/ijgc-2021-002565
Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5.
pubmed: 24219974
doi: 10.1016/j.ijgo.2013.10.001
WHO Classification of Tumours Editorial Board. Female Genital Tumours: WHO Classification of Tumours: IARC, Lyon, France, 2020.
Lheureux S, Braunstein M, Oza AM. Epithelial Ovarian Cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304.
pubmed: 31099893
doi: 10.3322/caac.21559
Vergote I, González-Martín A, Ray-Coquard I, Harter P, Colombo N, Pujol P, et al. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 2022;33(3):276–87.
pubmed: 34861371
doi: 10.1016/j.annonc.2021.11.013
Trimbos JB, Timmers P, Pecorelli S, Coens C, Ven K, van der Burg M, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst. 2010;102(13):982–7.
pubmed: 20445161
pmcid: 2911043
doi: 10.1093/jnci/djq149
Chan JK, Tian C, Fleming GF, Monk BJ, Herzog TJ, Kapp DS, et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(3):301–6.
pubmed: 19945740
doi: 10.1016/j.ygyno.2009.10.073
Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2015;2015(12):CD004706.
pubmed: 26676202
pmcid: 6457737
Du Bois A, Reuss A, Pujade-Lauraine E, Harter Ph, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynae- kologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115(6):1234–44.
pubmed: 19189349
doi: 10.1002/cncr.24149
Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Eng J Med. 2019;380:822–32.
doi: 10.1056/NEJMoa1808424
Jean-Marc C, Loic C, Fabrice L, Ignace V, Clémentine J, Romuald W, Christophe P, et al. Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial. J Clin Oncol. 2024;42:17.
Fotopoulou C, Concin N, Planchamp F, Morice Ph, Vergote I, du Bois A, et al. Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. Int J Gynecol Cancer. 2020;30(4):436–40.
pubmed: 32086362
doi: 10.1136/ijgc-2020-001248
Muñoz Martín AJ, Gallardo Díaz E, García Escobar I, Macías Montero R, Martínez-Marín V, Pachón Olmos V, et al. SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clin Transl Oncol. 2020;22(2):171–86.
pubmed: 31981080
doi: 10.1007/s12094-019-02263-z
Clamp A, James E, McNeish I, Dean A, Kim J-W, O’Donnell DM, et al. Weekly dose-dense chemo- therapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019;394:2084–95.
pubmed: 31791688
pmcid: 6902268
doi: 10.1016/S0140-6736(19)32259-7
Falandry C, Pommeret F, Gladieff L, Tinquaut F, Lorusso D, Mouret-Reynier M-A, et al. Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study. The Lancet. 2022;3(3):e176–85.
pubmed: 36098291
Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;11:CD005340.
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.
pubmed: 22204724
doi: 10.1056/NEJMoa1104390
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.
pubmed: 22204725
doi: 10.1056/NEJMoa1103799
Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, et al. Optimal treatment duration of bevacizumab as front-line therapy for advanced ovarian cancer: AGO- OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 open-label randomized phase III trial. J Clin Oncol. 2023;41(4):893–902.
pubmed: 36332161
doi: 10.1200/JCO.22.01010
Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495–505.
pubmed: 30345884
doi: 10.1056/NEJMoa1810858
Ray Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as firstline maintenance in ovarian cancer. N Engl J Med. 2019;381:2416–28.
pubmed: 31851799
doi: 10.1056/NEJMoa1911361
Gonzalez-Martín A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391–402.
pubmed: 31562799
doi: 10.1056/NEJMoa1910962
Li N, Zhu J, Yin R, Wang J, Pan L, Kong B, et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME study): a randomized, double-blind, placebo controlled, phase 3 trial. Gynecol Oncol. 2022;166:S50–1. https://doi.org/10.1016/S0090-8258(22)01298-7 .
doi: 10.1016/S0090-8258(22)01298-7
Monk BJ, Parkinson C, Lim MC, O’Malley DM, Oaknin A, Wilson MK, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). Clin Oncol. 2022;40(34):3952–64.
DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol. 2023;41(3):609–17.
pubmed: 36082969
doi: 10.1200/JCO.22.01549
Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2023;34(8):681–92.
pubmed: 37211045
doi: 10.1016/j.annonc.2023.05.005
Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC, et al. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol. 2017;35(10):1103–11.
pubmed: 28221866
pmcid: 5455356
doi: 10.1200/JCO.2016.71.0632
Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, et al. Fifth ovarian cancer consensus conference of the gynecologic cancer InterGroup: recurrent disease. Ann Oncol. 2017;28:727–32.
pubmed: 27993805
doi: 10.1093/annonc/mdw663
Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med. 2021;385:2123–31.
pubmed: 34874631
doi: 10.1056/NEJMoa2103294
Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):439–49.
pubmed: 33705695
doi: 10.1016/S1470-2045(21)00006-1
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Wlalker JL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:779–91.
pubmed: 28438473
pmcid: 5715461
doi: 10.1016/S1470-2045(17)30279-6
Hagan Vetter M, Khan A, Backes FJ, Bixel K, Cohn DE, Copeland LJ, et al. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. Gynecol Oncol. 2019;152(2):316–32.
doi: 10.1016/j.ygyno.2018.10.037
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäempää J, Sessa C, et al. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6–12 months after last platinum line. Br J Cancer. 2023;128(8):1503–13.
pubmed: 36759720
pmcid: 10070417
doi: 10.1038/s41416-022-02108-7
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter Ph, Holy F, et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(5):699–709.
pubmed: 32305099
doi: 10.1016/S1470-2045(20)30142-X
Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021;22(2):267–76.
pubmed: 33539744
doi: 10.1016/S1470-2045(20)30637-9
Pujade-Lauraine E, Lederman J, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and BRCA1/2 mutation (SOLO2/ENGOT-OV21): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–84.
pubmed: 28754483
doi: 10.1016/S1470-2045(17)30469-2
Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–64.
pubmed: 27717299
doi: 10.1056/NEJMoa1611310
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo controlled, phase 3 trial. Lancet. 2017;390:1949–61.
pubmed: 28916367
pmcid: 5901715
doi: 10.1016/S0140-6736(17)32440-6
Frenel JS, Kim JW, Aryal N, Asher R, Berton D, Vidal L, et al. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancerprogressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Ann Oncol. 2022;33(10):1021–8.
pubmed: 35772665
doi: 10.1016/j.annonc.2022.06.011
Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marmé F, Lindemann K, et al. LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): phase IIIb OReO/ENGOT Ov-38 trial. Ann Oncol. 2021;32(S5):S1308–9.
doi: 10.1016/j.annonc.2021.08.2110
McMullen M, Madariaga A, Lheureux S. New approaches for targeting platinum-resistant ovarian cancer. Semin Cancer Biol. 2021;77:167–81.
pubmed: 32871277
doi: 10.1016/j.semcancer.2020.08.013
Monk BJ, Herzog TJ, Wang G, Triantos S, Maul S, Knoblauch R, et al. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylatedliposomal doxorubicin therapy for recurrent ovarian cancer. Gynecol Oncol. 2020;156(3):535–44.
pubmed: 31924332
doi: 10.1016/j.ygyno.2019.12.043
Poveda AM, Selle F, Hilpert F, Reuss A, Savarese A, Vergote I, et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol. 2015;33:3836–8.
pubmed: 26282651
doi: 10.1200/JCO.2015.63.1408
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389(23):2162–74.
pubmed: 38055253
doi: 10.1056/NEJMoa2309169
Morice PM, Leary A, Dolladille C, Chrétien B, Poulain L, González-Martín A, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021;8(2):e122–34.
pubmed: 33347814
doi: 10.1016/S2352-3026(20)30360-4